Spyre Therapeutics, Inc. SYRE Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s proceeds from exercises of stock options and other stock issuances?
- Spyre Therapeutics, Inc. (SYRE) reported proceeds from exercises of stock options and other stock issuances of $2.68M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s proceeds from exercises of stock options and other stock issuances changed year-over-year?
- Spyre Therapeutics, Inc.'s proceeds from exercises of stock options and other stock issuances increased by 1127.5% year-over-year, from $218K to $2.68M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s proceeds from exercises of stock options and other stock issuances?
- Over 3 years (2021 to 2025), Spyre Therapeutics, Inc.'s proceeds from exercises of stock options and other stock issuances has grown at a 20.2% compound annual growth rate (CAGR), from $1.9M to $3.31M.